Boehringer Ingelheim International GmbH
In summer 2012, Polyphor Ltd announced the signing of a research collaboration and license agreement with Boehringer Ingelheim International GmbH, under which Polyphor will apply its proprietary MacroFinder® drug discovery technology to identify and optimize novel macrocyclic drug candidates addressing therapeutic targets selected by Boehringer Ingelheim. In return, Polyphor will receive from Boehringer Ingelheim an up-front payment, research funding and milestone payments as candidate molecules progress through the drug discovery process, preclinical and clinical development and onto the market. In addition, Polyphor is eligible for undisclosed royalties on the commercial sales of any approved products.

